Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Disparities

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Keeping current with the burden and risk factors of Alzheimer disease and other dementias (ADOD) from global to national levels is critical for healthcare planning, prevention strategies, and the allocation of resources. In this descriptive epidemiological analysis, we conducted a secondary analysis of global burden of disease data to examine the epidemiological burden of ADOD from 1990 to 2021 across global, regional and national levels. The study assessed age-standardized rates of incidence, prevalence, mortality, disability-adjusted life years, years lived with disability, and years of life lost. In 2021, global ADOD burden showed notable geographical disparities across all metrics. The highest incidence and prevalence rates were reported in China, while Gabon recorded the highest death rates. The Democratic Republic of the Congo observed the highest DALYs rates. From 1990 to 2021, age-standardized ADOD rates increased globally. Notably, China saw significant increases in incidence, prevalence, and years lived with disability, while Indonesia and Eritrea reported the highest rises in deaths and years of life lost, respectively. The burden growth was most pronounced in high-middle and middle socio-demographic index regions. The study also highlighted the impact of metabolic risk factors on the ADOD-related disability-adjusted life years across regions and sexes. Based on the findings of significant geographical heterogeneity in the escalating global burden of ADOD and its close association with specific risk factors, public health intervention strategies must be both geographically targeted and closely aligned with the predominant risk factors in each region to optimize resource allocation and maximize prevention and control efficiency.

What this study adds

Evidence grade: Low

This descriptive analysis of global burden of disease data from 1990 to 2021 found escalating age-standardized Alzheimer's disease and other dementias rates with notable geographical disparities and an association with metabolic risk factors. The authors call for geographically targeted public health strategies aligned with predominant risk factors, but no treatment, cure, or prevention was tested.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cheng, F.-S., Lei, J.-X., Zhang, J., Wang, J., & Sun, F. (2025). Global burden of Alzheimer disease and other dementias reveals escalating geographical disparities and metabolic risks: A comprehensive analysis of 1990–2021 data. Medicine. https://doi.org/10.1097/md.0000000000046219

Vancouver

Cheng F.-S, Lei J.-X, Zhang J, Wang J, Sun F. Global burden of Alzheimer disease and other dementias reveals escalating geographical disparities and metabolic risks: A comprehensive analysis of 1990–2021 data. Medicine. 2025. doi:10.1097/md.0000000000046219. PMID: 41327665.

BibTeX

@article{cheng2025-41327665,
  author  = {Cheng, Fang-Shuo and Lei, Jia-Xin and Zhang, Jian and Wang, Jinghua and Sun, Fen},
  title   = {{Global burden of Alzheimer disease and other dementias reveals escalating geographical disparities and metabolic risks: A comprehensive analysis of 1990–2021 data}},
  journal = {Medicine},
  year    = {2025},
  doi     = {10.1097/md.0000000000046219},
  pmid    = {41327665},
  url     = {https://doi.org/10.1097/md.0000000000046219}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This descriptive analysis of global burden of disease data from 1990 to 2021 found escalating age-standardized Alzheimer's disease and other dementias rates with notable geographical disparities and an association with metabolic risk factors. The authors call for geographically targeted public health strategies aligned with predominant risk factors, but no treatment, cure, or prevention was tested.

Study details

How this study scored 34/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 34 of 100.34 of 100 points earned66 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Medicine)
Journal's citation record 3 / 4 Medicine: journal h-index 285 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Fen Sun: h-index 18 (OpenAlex, whole career)
Institution's track record 0 / 3 Hangzhou Normal University: institution h-index 311 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41327665)
Free to read 2 / 2 Free to read
Total 34 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disparities from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disparities

See all studies in Disparities →